Congress Proposes Public-Private Partnership For CIR
This article was originally published in The Rose Sheet
Executive Summary
In reports accompanying draft fiscal 2016 funding bills, both House and Senate committees recommend that FDA work with industry to explore formalizing the Cosmetic Ingredient Review via a public-private partnership similar to that in place with the U.S. Pharmacopeial Convention.
You may also be interested in...
FDA Balks At CIR Public-Private Partnership In FY 2017 Budget Request
Based on its fiscal 2017 budget justification, FDA does not support a congressional proposal to formalize Cosmetic Ingredient Review safety assessments through a public-private partnership. The agency still intends to prepare a report on the subject, as directed by Senate and House appropriations committees, but characterizes the proposed framework as "inappropriate."
CIR Model For Ingredient Assessment Piques China's Interest
Regulatory authorities in developing countries, including China, are showing increasing interest in the Cosmetic Ingredient Review process, with a view to adapting it for use in their own regions, according to CIR Director Lillian Gill.
ICCR Adds Cosmetic Product Preservation To Agenda For Ninth Meeting
During a public preparatory meeting in advance of the ninth International Cooperation for Cosmetics Regulation summit, FDA Office of Cosmetics and Colors Director Linda Katz said that the topic of cosmetic product preservation will be included on the agenda for the first time. Animal-testing alternatives, allergens and trace impurities also are up for discussion, continuing regulators' work from last year on those topics.